The global Hypogonadism Drug market size is predicted to grow from US$ 3847 million in 2025 to US$ 5335 million in 2031; it is expected to grow at a CAGR of 5.6% from 2025 to 2031.

There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.

Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.

Infinity Market Research newest research report, the ?Hypogonadism Drug Industry Forecast? looks at past sales and reviews total world Hypogonadism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hypogonadism Drug sales for 2025 through 2031. With Hypogonadism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypogonadism Drug industry.

This Insight Report provides a comprehensive analysis of the global Hypogonadism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypogonadism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Hypogonadism Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypogonadism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypogonadism Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Hypogonadism Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Injection
    Capsule

Segmentation by Application:

    Hospital
    Pharmacy
    Specialist Clinic
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Allergan
    AbbVie
    Endo Pharmaceuticals
    Pfizer Inc.
    Clarus Therapeutics, Inc.
    Aytu BioScience, Inc.
    Antares Pharma
    Upsher-Smith Laboratories, Inc.
    Beijing Shuanghe Pharmaceutical Co., Ltd
    Tianjin Jinyao Amino Acid Co., Ltd
    Shanghai General Pharmaceutical Co., Ltd
    Tianjin Lisheng Pharmaceutical Co., Ltd
    Chengde Jiulong Pharmaceutical Co., Ltd
    Harbin Pharmaceutical Group
    Shenyang Keda Pharmaceutical Co., Ltd
    Zhejiang Xianju Pharmaceutical Co., Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hypogonadism Drug market?
What factors are driving Hypogonadism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hypogonadism Drug market opportunities vary by end market size?
How does Hypogonadism Drug break out by Type, by Application?